Published in Lakartidningen on November 08, 2000
[Pneumococcal vaccine for the elderly--ineffective but cost-efficient?]. Lakartidningen (2000) 0.75
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
The economic cost of brain disorders in Europe. Eur J Neurol (2012) 3.53
Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics (1993) 2.96
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation (1996) 2.23
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol (2008) 2.12
Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health (2006) 1.96
Conversion factor instability in international comparisons of health care expenditure. J Health Econ (1991) 1.83
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med (1997) 1.79
Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy (1991) 1.77
What are the priorities for prevention and control of non-communicable diseases and injuries in sub-Saharan Africa and South East Asia? BMJ (2012) 1.72
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Funding of headache research in Europe. Cephalalgia (2007) 1.71
Outcome measurement in economic evaluation. Health Econ (1997) 1.69
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract (2009) 1.66
Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med (2000) 1.63
Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum (1999) 1.61
Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry (2006) 1.61
An econometric analysis of health care expenditure: a cross-section study of the OECD countries. J Health Econ (1992) 1.60
Inter-institutional information exchange in healthcare. Int J Biomed Comput (1992) 1.52
Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis. Structure (1997) 1.42
The Swedish National Register for lumbar spine surgery: Swedish Society for Spinal Surgery. Acta Orthop Scand (2001) 1.41
[Prognostic markers in reflux esophagitis better than wrapped up recommendations]. Lakartidningen (1992) 1.40
Health-related quality of life (EQ-5D) before and one year after surgery for lumbar spinal stenosis. J Bone Joint Surg Br (2009) 1.37
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36
Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol (2001) 1.34
Resource allocation to brain research in Europe (RABRE). Eur J Neurosci (2006) 1.34
Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int (2007) 1.33
The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand (1997) 1.27
Diabetes--the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl (1983) 1.23
A large Escherichia coli O157 outbreak in Sweden associated with locally produced lettuce. Foodborne Pathog Dis (2008) 1.22
Visual analog scales for interpretation of back and leg pain intensity in patients operated for degenerative lumbar spine disorders. Spine (Phila Pa 1976) (2001) 1.21
Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int (2006) 1.21
Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med (1999) 1.18
Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int (2001) 1.18
Five common fallacies in estimating the economic gains of early discharge. Soc Sci Med Med Econ (1980) 1.17
Willingness to pay for antihypertensive therapy--results of a Swedish pilot study. J Health Econ (1991) 1.15
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ (2008) 1.14
Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg (2000) 1.14
Diabetes: the cost of illness in Sweden. J Intern Med (1998) 1.13
Economic evaluation of influenza vaccination. Assessment for The Netherlands. Pharmacoeconomics (1999) 1.13
Measurement and modelling of sequence-specific pKa values of lysine residues in calbindin D9k. J Mol Biol (1996) 1.13
Health-related quality of life in patients before and after surgery for a herniated lumbar disc. J Bone Joint Surg Br (2005) 1.11
The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy (1997) 1.10
The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture. Osteoporos Int (2013) 1.08
The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract (2006) 1.08
No relationship between epidural fibrosis and sciatica in the lumbar postdiscectomy syndrome. A study with contrast-enhanced magnetic resonance imaging in symptomatic and asymptomatic patients. Spine (Phila Pa 1976) (1995) 1.06
Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int (2008) 1.06
The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity (2011) 1.04
The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics (1998) 1.02
Selective or routine intraoperative cholangiography: a cost-effectiveness analysis. World J Surg (1980) 1.00
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int (2004) 0.99
The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost (2003) 0.99
Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis (2000) 0.97
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int (2006) 0.96
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int (2006) 0.96
Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia (2008) 0.96
Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health (2006) 0.96
The interpretation of results of economic evaluation: explicating the value of health. Health Econ (1998) 0.96
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol (2007) 0.95
Costs of Mini Mental State Examination-related cognitive impairment. Pharmacoeconomics (1999) 0.94
Binding of Ca2+ to calbindin D9k: structural stability and function at high salt concentration. Biochemistry (1994) 0.94
Electrostatic contributions to the binding of Ca2+ in calbindin mutants. A Monte Carlo study. Biophys Chem (1990) 0.94
The costs of treating hypertension--an analysis of different cut-off points. Health Policy (1991) 0.92
The determinants of health expenditure in the OECD countries: a pooled data analysis. Dev Health Econ Public Policy (1998) 0.92
Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital. J Hosp Infect (2008) 0.91
Ion-binding properties of calbindin D9k: a Monte Carlo simulation study. Biochemistry (1991) 0.91
Intervention thresholds for osteoporosis. Bone (2002) 0.90
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden. Osteoporos Int (2008) 0.89
Making cost assessments based on RCTs more useful to decision-makers. Health Policy (1996) 0.89
Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care (2000) 0.89
The effect of protein concentration on ion binding. Proc Natl Acad Sci U S A (1995) 0.89
Theory for electrostatic interaction chromatography of proteins. Anal Chem (1991) 0.88
Resource use and costs associated with patients treated for depression in primary care. Eur J Health Econ (2007) 0.88
Focusing of the electrostatic potential at EF-hands of calbindin D(9k): titration of acidic residues. Proteins (2001) 0.88
The cost of screening for hypercholesterolaemia--results from a clinical trial in Swedish primary health care. Scand J Clin Lab Invest (1993) 0.88
Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial. Eur J Heart Fail (2008) 0.88
The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int J Clin Pract (2008) 0.87
Personality traits predicting weight loss outcome in obese patients. Acta Psychiatr Scand (1986) 0.87
Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl (1989) 0.87
Ionization behavior of acidic residues in calbindin D(9k). Proteins (1999) 0.87
Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis (2010) 0.87
Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience. Int J Tuberc Lung Dis (2013) 0.86
Non-invasive measurement of systolic blood pressure on the arm utilising photoplethysmography: development of the methodology. Med Biol Eng Comput (2005) 0.86
The costs of treating hypertension in Sweden. An empirical investigation in primary health care. Scand J Prim Health Care (1991) 0.86
A pooled cross-section analysis of the health care expenditures of the OECD countries. Dev Health Econ Public Policy (1992) 0.86
Cost effectiveness of foldable multifocal intraocular lenses compared to foldable monofocal intraocular lenses for cataract surgery. Br J Ophthalmol (2004) 0.86
Body image in dentistry. J Prosthet Dent (1970) 0.86
Ruptured mycotic aneurysm of the abdominal aorta: a serious complication of intravesical instillation bacillus Calmette-Guerin therapy. J Urol (1998) 0.86
Economic evaluation of drug therapy: a review of the contingent valuation method. Pharmacoeconomics (1992) 0.85
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther (1999) 0.85
Psychiatric ratings in occupational health research: a study of mental symptoms in lacquerers. Am J Ind Med (1980) 0.85
Fairness in service choice: an important yet underdeveloped path to universal coverage. Trop Med Int Health (2011) 0.85
A critical investigation of the Tanford-Kirkwood scheme by means of Monte Carlo simulations. Protein Sci (2001) 0.85
Calbindin D(9k): a protein optimized for calcium binding at neutral pH. Biochemistry (2001) 0.84
Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial. J Intern Med (2004) 0.84